Covidien plc has announced the European launch of its Pipeline™ Flex embolization device at the annual Live Interventional Neuroradiology & Neurosurgery Course (LINNC), held in Paris June 23-25.
According to the Brain Aneurysm Foundation, there are nearly 500,000 deaths worldwide each year caused by brain aneurysms and half the victims are younger than 50 years of age.
Covidien’s first-generation Pipeline™ embolization device has been used to treat patients in Europe since 2009. It has been the only flow diversion device commercially available in the U.S. since it was approved by the U.S. Food and Drug Administration in April 2011. Effectively these devices cut off blood flow to the aneurysm, while reconstructing the diseased section of the parent vessel.
Fitting into the company’s broad line of neurovascular products to treat unruptured brain aneurysms, Covidien’s newer Pipeline Flex device features a braided cylindrical mesh tube that is implanted across the base or neck of the aneurysm. The device is repositionable and designed for optimal accuracy and controlled placement.
Among other features, it includes an instant braid release system that Covidien says makes it even easier to place. For that reason, Covidien describes its device as “next generation”.
“The Pipeline Flex embolization device is the next advancement in flow diversion, combining our clinically-proven braid design with a new delivery system designed to offer even more accuracy and control when performing these advanced procedures inside the brain,” said Brett Wall, president, Neurovascular, Covidien.
Source: Covidien, plc., Business Wire